Intravenous injection of allogenic canine mesenchymal stem cells in 40 client-owned dogs: a safety assessment in veterinary clinical trials

• Published in: BMC veterinary research 2024-08, Vol.20 (1), p.375-7
• Main Authors: Cho, Hee-Seon, Song, Woo-Jin, Nam, Aryung, Li, Qiang, An, Ju-Hyun, Ahn, Jin-Ok, Kim, Hyun-Tae, Park, Su-Min, Ryu, Min-Ok, Kim, Myung-Chul, Kim, Ju-Hun, Youn, Hwa-Young
• Format: Article
• Language: English
• Subjects: Adipose tissue; Adipose Tissue - cytology; Adverse effects; Allografts; Animals; Blood tests; Body fat; Care and treatment; Cell therapy; Cellular therapy; Clinical trials; Dermatitis; Diseases; Dog; Dog Diseases - therapy; Dogs; Edema; Female; Flow cytometry; Health aspects; Hospitals; Inflammatory bowel disease; Injections, Intravenous; Injections, Intravenous - veterinary; Intravenous administration; Intravenous injection; Kidney diseases; Male; Mesenchymal Stem Cell Transplantation - adverse effects; Mesenchymal Stem Cell Transplantation - methods; Mesenchymal Stem Cell Transplantation - veterinary; Mesenchymal Stem Cells; Pets; Retrospective Studies; Safety; Side effects; Stem cell transplantation; Stem cells; Testing; Transplantation, Homologous - veterinary; Tumorigenesis; Tumors; Ultrasonic imaging; Veterinary medicine
• ISSN: 1746-6148; 1746-6148
• DOI: 10.1186/s12917-024-04216-3

The aim of this study was to evaluate the adverse effects of allogeneic mesenchymal stem cells (MSCs) transplanted via intravenous infusion in dogs and examine their safety. We performed a retrospective analysis of various clinical assessments, including physical examination, blood tests, and radiographs, and monitored the formation of neoplasms during a 6-month follow-up period in 40 client-owned dogs that received intravenous infusion of adipose tissue-derived MSCs (AT-MSCs) for the treatment of various underlying diseases between 2012 and 2018. No significant adverse effects of MSC therapy were detected by clinical assessment, blood tests, or radiographic examination in the 6-month follow-up period after the first MSC treatment. Additionally no new neoplasms were observed during this period. To our knowledge, this study is the first to evaluate the safety aspects (≥ 6 months) associated with intravenous allogeneic AT-MSC infusion. These results suggest that allogenic AT-MSC infusion could be a useful and relatively safe therapeutic approach in canines.